Downregulation of GLUT3 impairs STYK1/NOK-mediated metabolic reprogramming and proliferation in NIH-3T3 cells

Weiye Shi1, Yu Fu1, Yingze Wang1

  • 1Cell Engineering Laboratory, College of Biological Science and Engineering, Hebei University of Science and Technology, Shijiazhuang, Hebei 050018, P.R. China.

Oncology Letters
|May 31, 2021
PubMed

Insights

Serine threonine tyrosine kinase 1 (STYK1) promotes cancer by increasing glucose metabolism. This study shows glucose transporter 3 (GLUT3) is crucial for STYK1-driven aerobic glycolysis and cell proliferation, suggesting GLUT3 as a potential cancer therapy target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metabolism

Background:

  • Serine threonine tyrosine kinase 1 (STYK1), also known as novel oncogene with kinase domain (NOK), promotes carcinogenesis and tumorigenesis.
  • STYK1 enhances aerobic glycolysis, a hallmark of cancer.
  • Glucose transporters (GLUTs) are vital for glucose metabolism and tumorigenesis, but their role in STYK1-mediated events is unknown.

Purpose of the Study:

  • To investigate the role of glucose transporter 3 (GLUT3) in STYK1/NOK-driven biological processes.
  • To determine if GLUT3 mediates STYK1/NOK-induced aerobic glycolysis and cell proliferation.

Main Methods:

  • Assessed glucose consumption and lactate production.
  • Utilized RT-qPCR and western blotting to analyze gene and protein expression.
  • Performed MTT and Transwell assays to evaluate cell proliferation and migration.

Main Results:

  • Downregulation of GLUT3 impaired STYK1/NOK-induced glucose uptake and lactate production.
  • GLUT3 knockdown attenuated STYK1/NOK-induced increases in key glycolytic enzyme expression.
  • Knockdown of GLUT3 significantly decreased STYK1/NOK-triggered cell proliferation and migration.

Conclusions:

  • GLUT3 plays a prominent role in STYK1/NOK-driven aerobic glycolysis and cell proliferation.
  • These findings highlight GLUT3 as a key mediator of STYK1 oncogenic activity.
  • GLUT3 represents a potential therapeutic target for cancers associated with STYK1/NOK.

Related Concept Videos